Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Diet-regulated behavior: FVB/N mice fed a lean diet exhibit increased nocturnal bouts of aggression between littermates.

Murph MM, Liu S, Jia W, Nguyen H, MacFarlane MA, Smyth SS, Kuppa SS, Dobbin KK.

Lab Anim. 2019 Mar 16:23677219834582. doi: 10.1177/0023677219834582. [Epub ahead of print]

PMID:
30880558
2.

Direct identification of microribonucleic acid miR-451 from plasma using liquid chromatography mass spectrometry.

Basiri B, Sutton JM, Hooshfar S, Byrnes CC, Murph MM, Bartlett MG.

J Chromatogr A. 2019 Jan 11;1584:97-105. doi: 10.1016/j.chroma.2018.11.029. Epub 2018 Nov 16.

PMID:
30502920
3.

miR-122-5p Expression and Secretion in Melanoma Cells Is Amplified by the LPAR3 SH3-Binding Domain to Regulate Wnt1.

Byrnes CC, Jia W, Alshamrani AA, Kuppa SS, Murph MM.

Mol Cancer Res. 2019 Jan;17(1):299-309. doi: 10.1158/1541-7786.MCR-18-0460. Epub 2018 Sep 28.

PMID:
30266753
4.

Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.

Kuppa SS, Jia W, Liu S, Nguyen H, Smyth SS, Mills GB, Dobbin KK, Hardman WJ, Murph MM.

Cancer Lett. 2018 Sep 28;432:84-92. doi: 10.1016/j.canlet.2018.05.037. Epub 2018 May 31.

PMID:
29859298
5.

Assessing the Interplay between the Physicochemical Parameters of Ion-Pairing Reagents and the Analyte Sequence on the Electrospray Desorption Process for Oligonucleotides.

Basiri B, Murph MM, Bartlett MG.

J Am Soc Mass Spectrom. 2017 Aug;28(8):1647-1656. doi: 10.1007/s13361-017-1671-6. Epub 2017 Apr 12.

6.

The Role of Fluorinated Alcohols as Mobile Phase Modifiers for LC-MS Analysis of Oligonucleotides.

Basiri B, van Hattum H, van Dongen WD, Murph MM, Bartlett MG.

J Am Soc Mass Spectrom. 2017 Jan;28(1):190-199. doi: 10.1007/s13361-016-1500-3. Epub 2016 Sep 19.

7.

Lysophosphatidic Acid Mediates Activating Transcription Factor 3 Expression Which Is a Target for Post-Transcriptional Silencing by miR-30c-2-3p.

Nguyen HT, Jia W, Beedle AM, Kennedy EJ, Murph MM.

PLoS One. 2015 Sep 29;10(9):e0139489. doi: 10.1371/journal.pone.0139489. eCollection 2015.

8.

Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.

Altman MK, Alshamrani AA, Jia W, Nguyen HT, Fambrough JM, Tran SK, Patel MB, Hoseinzadeh P, Beedle AM, Murph MM.

Cancer Lett. 2015 Dec 1;369(1):175-83. doi: 10.1016/j.canlet.2015.08.012. Epub 2015 Aug 28.

9.

Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer.

Hooks SB, Murph MM.

Future Med Chem. 2015 Aug;7(12):1483-9. doi: 10.4155/fmc.15.81. Epub 2015 Aug 21. Review.

10.

Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Murph MM, Jiang GW, Altman MK, Jia W, Nguyen DT, Fambrough JM, Hardman WJ, Nguyen HT, Tran SK, Alshamrani AA, Madan D, Zhang J, Prestwich GD.

Bioorg Med Chem. 2015 Sep 1;23(17):5999-6013. doi: 10.1016/j.bmc.2015.06.054. Epub 2015 Jul 2.

11.

PKA-type I selective constrained peptide disruptors of AKAP complexes.

Wang Y, Ho TG, Franz E, Hermann JS, Smith FD, Hehnly H, Esseltine JL, Hanold LE, Murph MM, Bertinetti D, Scott JD, Herberg FW, Kennedy EJ.

ACS Chem Biol. 2015 Jun 19;10(6):1502-10. doi: 10.1021/acschembio.5b00009. Epub 2015 Mar 25.

12.

The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells.

Jia W, Tran SK, Ruddick CA, Murph MM.

Cancer Lett. 2015 Jan 28;356(2 Pt B):589-96. doi: 10.1016/j.canlet.2014.10.001. Epub 2014 Oct 7.

PMID:
25304369
13.

Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?

Nguyen HT, Tian G, Murph MM.

Front Oncol. 2014 Apr 8;4:71. doi: 10.3389/fonc.2014.00071. eCollection 2014. Review.

14.

Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.

Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, Murph MM, Govindarajan R, Eblen ST, Greer SF, Hooks SB.

PLoS One. 2013;8(3):e60185. doi: 10.1371/journal.pone.0060185. Epub 2013 Mar 22.

15.

Biochemical pathways in cancer.

Breuer EK, Murph MM, Craven RJ.

Biochem Res Int. 2012;2012:268504. doi: 10.1155/2012/268504. Epub 2012 Nov 20. No abstract available.

16.

Regulator of G-Protein Signaling 5 Reduces HeyA8 Ovarian Cancer Cell Proliferation and Extends Survival in a Murine Tumor Model.

Altman MK, Nguyen DT, Patel SB, Fambrough JM, Beedle AM, Hardman WJ, Murph MM.

Biochem Res Int. 2012;2012:518437. doi: 10.1155/2012/518437. Epub 2012 Jun 25.

17.

MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9.

Jia W, Eneh JO, Ratnaparkhe S, Altman MK, Murph MM.

Mol Cancer Res. 2011 Dec;9(12):1732-45. doi: 10.1158/1541-7786.MCR-11-0245. Epub 2011 Oct 24.

19.

Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers.

Nguyen GH, Murph MM, Chang JY.

Cancers (Basel). 2011 Mar;3(1):1232-52. doi: 10.3390/cancers3011232.

20.

Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.

Hooks SB, Callihan P, Altman MK, Hurst JH, Ali MW, Murph MM.

Mol Cancer. 2010 Nov 2;9:289. doi: 10.1186/1476-4598-9-289.

21.

Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.

Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, Davies MA, Murph MM.

Mol Cancer. 2010 Jun 9;9:140. doi: 10.1186/1476-4598-9-140.

22.

Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.

Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB.

PLoS One. 2009;4(5):e5583. doi: 10.1371/journal.pone.0005583. Epub 2009 May 15.

23.

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.

Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB.

J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42. doi: 10.1093/jnci/djn378. Epub 2008 Nov 11.

24.

Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients.

Murph MM, Smith DL, Hennessy B, Lu Y, Joy C, Coombes KR, Mills GB.

Adv Exp Med Biol. 2008;622:183-95. doi: 10.1007/978-0-387-68969-2_15. Review. No abstract available.

PMID:
18546628
25.

Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.

Murph MM, Nguyen GH, Radhakrishna H, Mills GB.

Biochim Biophys Acta. 2008 Sep;1781(9):547-57. doi: 10.1016/j.bbalip.2008.04.007. Epub 2008 Apr 29. Review.

26.

Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells.

Murph MM, Hurst-Kennedy J, Newton V, Brindley DN, Radhakrishna H.

Mol Cancer Res. 2007 Nov;5(11):1201-11.

27.

Agonist-induced endocytosis of lysophosphatidic acid-coupled LPA1/EDG-2 receptors via a dynamin2- and Rab5-dependent pathway.

Murph MM, Scaccia LA, Volpicelli LA, Radhakrishna H.

J Cell Sci. 2003 May 15;116(Pt 10):1969-80. Epub 2003 Mar 26.

28.

Transfer of M2 muscarinic acetylcholine receptors to clathrin-derived early endosomes following clathrin-independent endocytosis.

Delaney KA, Murph MM, Brown LM, Radhakrishna H.

J Biol Chem. 2002 Sep 6;277(36):33439-46. Epub 2002 Jul 1.

Supplemental Content

Loading ...
Support Center